Who are Ditropan Xl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ecclock, Yupelri, Sanctura, Enablex, Spiriva, HEXOCYCLIUM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxybutynin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ditropan Xl — Competitive Intelligence Brief

Ditropan Xl (OXYBUTYNIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic Muscarinic Antagonist. Area: Metabolic.

marketed Cholinergic Muscarinic Antagonist Muscarinic acetylcholine receptor M3 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ditropan Xl (OXYBUTYNIN) — Hisamitsu Pharmaceutical Co., Inc.. Oxybutynin works by blocking the action of a chemical called acetylcholine on the bladder muscle, reducing spasms and urgency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ditropan Xl TARGET	OXYBUTYNIN	Hisamitsu Pharmaceutical Co., Inc.	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	1975-01-01
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Yupelri	REVEFENACIN	Mylan Ireland Ltd	marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Sanctura	TROSPIUM	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Enablex	DARIFENACIN	AbbVie	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M3	2004-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
HEXOCYCLIUM	HEXOCYCLIUM	AbbVie	marketed	hexocyclium	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinergic Muscarinic Antagonist class)

· 2 drugs in this class
AbbVie · 2 drugs in this class
Astellas Pharma · 1 drug in this class
Hisamitsu Pharmaceutical Co., Inc. · 1 drug in this class
Upjohn · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ditropan Xl — Competitive Intelligence Brief. https://druglandscape.com/ci/oxybutynin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab